ArticleNeurosurgical review2025
Butterfly glioblastoma: trends in therapeutic modalities, extent of resection and survival in the temozolomide era. a SEER-based study.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Butterfly gliomas: to biopsy or to ablate - a longitudinal cohort study.Journal of neuro-oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Butterfly glioblastoma (bGBM) is a rare type of GBM, thought to have extremely poor outcome and is generally considered "inoperable". The aim of this study was to investigate survival outcomes in bGBM over a long period, and to look for potential benefits of gross total resection (GTR). The data of 521 bGBM patients diagnosed between 2000 and 2021 from the Surveillance, Epidemiology, and End Results (SEER) database were obtained. The cohort was divided into 3 subgroups based on the year of diagnosis: pre-temozolomide era (pre-TMZ; 2000-2006), early TMZ era (2007-2016) and late TMZ era (2017-2021). chemotherapy was significantly more common in the TMZ group (51.9% vs. 36%, p = 0.007). The TMZ group was associated with nearly significantly improved OS (HR = 0.795, p = 0.067). On multivariate analysis, only radiation therapy was associated with improved survival in the pre-TMZ group (HR = 3.029, p = 0.001). However, in the TMZ group, 4 variables were associated with improved survival: chemotherapy (HR = 1.523, p = 0.049), radiation therapy (HR = 1.676, p = 0.006), surgery (HR = 1.402, p = 0.004) and age (HR = 1.031, p < 0.001). Both subtotal resection and GTR were significantly associated with favorable prognosis when compared to no surgery (HR = 0.607, p < 0.001 and HR = 0.467, p < 0.001; respectively). The rate of GTR was significantly higher in the late TMZ group (19.2% vs. 10.2%, p = 0.0013). GTR was significantly associated with improved OS in the late TMZ subgroup (HR = 1.846, p = 0.028). bGBM cases in the TMZ era are associated with increased rate of adjuvant chemotherapy as well as with improved OS, in comparison to pre-TMZ cases. The rate of GTR cases has significantly increased in recent years, and is associated with significantly increased rate of post operative adjuvant therapy. GTR patients who have received any kind of adjuvant therapy had significantly better OS when compared to non-GTR patients. bGBM should be treated like other operable GBM cases, using the appropriate, advanced surgical techniques. Clinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.